Founded in February 2021, 凌意生物 operates a leading animal‑model platform to support discovery, development and industrialization of gene therapies. The company focuses on metabolic, CNS and ophthalmic indications and aims to address the shortage of effective animal models for single‑gene genetic diseases. It is developing an FIC gene therapy pipeline and has assembled an international‑level discovery, development and commercialization team. Management emphasizes clinical‑need driven innovation, differentiated indications and global patent布局 and clinical progress according to investor commentary in the article. Following the new financing the company plans to establish its headquarters in Qianwan Biopark, Xiaoshan District, Hangzhou and will use proceeds to accelerate pipeline development and technology platform construction. Haoyue Capital served as exclusive financial advisor to the transaction. Lingyi Biotech, founded in February 2021, operates a global-leading rare-disease animal-model functional validation platform. The company focuses on source innovation in gene therapy, concentrating on metabolic, CNS, and ophthalmic genetic rare diseases. It has discovery, development, and industrialization teams with international-level experience in gene therapy and rare-disease R&D. Lingyi builds and validates animal models to address the shortage of effective models in rare-disease research. Its pipeline includes multiple globally leading gene-therapy projects currently in preclinical development. The company says it will continue deep work in gene therapy and aims to develop proprietary gene-therapy products to benefit patients.

Total raised

$30M

Funding rounds

2

Latest round

Series A

Latest activity

May 2023